{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T14:50:00Z","timestamp":1763563800308},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2011,10,8]],"date-time":"2011-10-08T00:00:00Z","timestamp":1318032000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Int J Clin Pharm"],"published-print":{"date-parts":[[2011,12]]},"DOI":"10.1007\/s11096-011-9567-1","type":"journal-article","created":{"date-parts":[[2011,10,6]],"date-time":"2011-10-06T23:27:40Z","timestamp":1317943660000},"page":"958-963","source":"Crossref","is-referenced-by-count":2,"title":["Evaluation of doripenem utilization and susceptibilities at a large urban hospital"],"prefix":"10.1007","volume":"33","author":[{"given":"Brett J.","family":"Balderson","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mary E. D.","family":"Yates","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Neelu P.","family":"Patil","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katie J.","family":"Suda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2011,10,8]]},"reference":[{"issue":"8","key":"9567_CR1","doi-asserted-by":"crossref","first-page":"3136","DOI":"10.1128\/AAC.48.8.3136-3140.2004","volume":"48","author":"RN Jones","year":"2004","unstructured":"Jones RN, Huynh HK, Biedenbach DJ. Activities of doripenem against drug-resistant clinical pathogens. Antimicrob Agents Chemother. 2004;48(8):3136\u201340.","journal-title":"Antimicrob Agents Chemother"},{"issue":"S3","key":"9567_CR2","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1086\/499819","volume":"42","author":"GH Talbot","year":"2006","unstructured":"Talbot GH, Bradley J, Edwards JE, Gilbert D, Scheld M, Bartlett JG. Bad bugs need drugs: an update on the development pipeline from the Antimicrobial Availability Task Force of the Infectious Diseases Society of America. Clin Infect Dis. 2006;42(S3):657\u201368.","journal-title":"Clin Infect Dis"},{"issue":"1","key":"9567_CR3","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1086\/380457","volume":"38","author":"DJ Diekema","year":"2004","unstructured":"Diekema DJ, BootsMiller BJ, Vaughn TE, Woolson RF, Yankey JW, Ernst EJ. Antimicrobial resistance trends and outbreak frequency. Clin Infect Dis. 2004;38(1):78\u201385.","journal-title":"Clin Infect Dis"},{"key":"9567_CR4","unstructured":"Infectious Diseases Society of America. Bad bugs, no drugs: as antibiotic R&D stagnates, a public health crisis brews. Alexandria,VA; 2004."},{"issue":"S2","key":"9567_CR5","doi-asserted-by":"crossref","first-page":"S82","DOI":"10.1086\/499406","volume":"42","author":"S Cosgrove","year":"2006","unstructured":"Cosgrove S. The relationship between resistance and patient outcomes: mortality, length of hospital stay and healthcare costs. Clin Infect Dis. 2006;42(S2):S82\u20139.","journal-title":"Clin Infect Dis"},{"issue":"1","key":"9567_CR6","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1378\/chest.118.1.146","volume":"118","author":"EH Ibrahim","year":"2000","unstructured":"Ibrahim EH, Sherman G, Ward S, Fraser VJ, Kollef MH. The Influence of inadequate antimicrobial treatment of bloodstream infections on patient outcomes in the ICU setting. Chest. 2000;118(1):146\u201355.","journal-title":"Chest"},{"issue":"3","key":"9567_CR7","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1080\/08998280.2008.11928422","volume":"21","author":"ND Greer","year":"2008","unstructured":"Greer ND. Doripenem (Doribax): the newest addition to the carbapenems. Proc (Bayl Univ Med Cent). 2008;21(3):337\u201341.","journal-title":"Proc (Bayl Univ Med Cent)"},{"issue":"5","key":"9567_CR8","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1093\/jac\/dkm059","volume":"59","author":"SGB Amyes","year":"2007","unstructured":"Amyes SGB, Walsh FM, Bradley JS. Best in class: a good principal for antibiotic usage to limit resistance development? J Antimicrob Chemother. 2007;59(5):825\u20136.","journal-title":"J Antimicrob Chemother"},{"issue":"4","key":"9567_CR9","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1097\/CCM.0b013e3181691b99","volume":"36","author":"J Chastre","year":"2008","unstructured":"Chastre J, Wunderink R, Prokocimer P, Lee M, Kaniga K, Friedland I. Efficacy and safety of intravenous infusion of doripenem versus imipenem in ventilator-associated pneumonia: a multi-center, randomized study. Crit Care Med. 2008;36(4):1089\u201396.","journal-title":"Crit Care Med"},{"issue":"7","key":"9567_CR10","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1185\/03007990802179255","volume":"24","author":"A Rea-Nieto","year":"2008","unstructured":"Rea-Nieto A, Niederman M, Lobo SM, Schroeder E, Lee M, Kaniga K. Efficacy and safety of doripenem versus piperacillin\/tazobactam in nosocomial pneumonia: a randomized, open-label, multi-center study. Curr Med Res Opin. 2008;24(7):2113\u201326.","journal-title":"Curr Med Res Opin"},{"issue":"14","key":"9567_CR11","doi-asserted-by":"crossref","first-page":"2021","DOI":"10.2165\/00003495-200868140-00007","volume":"68","author":"SJ Keam","year":"2008","unstructured":"Keam SJ. Doripenem A review of its use in the treatment of bacterial infections. Drugs. 2008;68(14):2021\u201357.","journal-title":"Drugs"},{"issue":"5","key":"9567_CR12","first-page":"789","volume":"3","author":"F Walsh","year":"2007","unstructured":"Walsh F. Doripenem: a new carbapenem antibiotic. A review of comparative antimicrobial and bactericidal activities. Ther Clin Risk Manag. 2007;3(5):789\u201394.","journal-title":"Ther Clin Risk Manag"},{"issue":"1","key":"9567_CR13","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.diagmicrobio.2004.12.008","volume":"52","author":"RN Jones","year":"2005","unstructured":"Jones RN, Sader HS, Fritsche TR. Comparative activity of doripenem and three other carbapenems tested against gram-negative bacilli with various \u03b2\u2013lactamase resistance mechanisms. Diagn Microbiol Infect Dis. 2005;52(1):71\u20134.","journal-title":"Diagn Microbiol Infect Dis"},{"key":"9567_CR14","unstructured":"Doribax [package insert]. Raritan, NJ: Ortho-McNeil Pharmaceutical Inc; 2007."},{"issue":"9","key":"9567_CR15","doi-asserted-by":"crossref","first-page":"3944","DOI":"10.1128\/AAC.49.9.3944-3947.2005","volume":"49","author":"SM Bhavnani","year":"2005","unstructured":"Bhavnani SM, Hammel JP, Cirincione BB, Wikler MA, Ambrose PG. Use of pharmacokinetic-pharmacodynamic target attainment analyses to support phase 2 and 3 dosing strategies for doripenem. Antimicrob Agents Chemother. 2005;49(9):3944\u20137.","journal-title":"Antimicrob Agents Chemother"},{"issue":"3","key":"9567_CR16","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/j.diagmicrobio.2008.06.016","volume":"62","author":"K Ikawa","year":"2008","unstructured":"Ikawa K, Morikawa N, Ikeda K, Ohge H, Sueda T. Pharmacodynamic assessment of doripenem in peritoneal fluid against gram-negative organisms: use of population pharmacokinetic modeling and Monte Carlo simulation. Diagn Microbiol Infect Dis. 2008;62(3):292\u20137.","journal-title":"Diagn Microbiol Infect Dis"},{"issue":"5","key":"9567_CR17","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1016\/j.clinthera.2008.04.019","volume":"30","author":"C Lucasti","year":"2008","unstructured":"Lucasti C, Jasovich A, Umeh O, Jiang J, Kaniga K, Friedland I. Efficacy and tolerability of IV doripenem versus meropenem in adults with complicated intra-abdominal infection: a phase III, prospective, multicenter, randomized, double-blind, noninferiority study. Clin Ther. 2008;30(5):868\u201383.","journal-title":"Clin Ther"},{"key":"9567_CR18","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1086\/648363","volume":"16","author":"DN Gerding","year":"1995","unstructured":"Gerding DN, Johnson S, Peterson LR, Muligan ME, Silva J Jr. Clostridium difficile-associated diarrhea and colitis. Infect Control Hosp Epidemiol. 1995;16:459\u201377.","journal-title":"Infect Control Hosp Epidemiol"},{"key":"9567_CR19","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1086\/382880","volume":"38","author":"WA Prescott Jr","year":"2004","unstructured":"Prescott WA Jr, DePestel DD, Ellis JJ, Regal RE. Incidence of carbapenem-associated allergic-type reactions among patients with versus patients without a reported penicillin allergy. Clin Infect Dis. 2004;38:1102\u20137.","journal-title":"Clin Infect Dis"},{"key":"9567_CR20","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1093\/jac\/dkh454","volume":"54","author":"M Sodhi","year":"2004","unstructured":"Sodhi M, Axtell SS, Callahan J, Shekar R. Is it safe to use carbapenems in patients with a history of allergy to penicillin? J Antimicrob Chemother. 2004;54:1155\u20137.","journal-title":"J Antimicrob Chemother"},{"key":"9567_CR21","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1592\/phco.27.1.137","volume":"27","author":"WA Prescott","year":"2007","unstructured":"Prescott WA, Kusmierski KA. Clinical importance of carbapenem hypersensitivity in patients with self-reported and documented penicillin allergy. Pharmacother. 2007;27:137\u201342.","journal-title":"Pharmacother."},{"key":"9567_CR22","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1345\/aph.1L486","volume":"43","author":"J Frumin","year":"2009","unstructured":"Frumin J, Gallagher JC. Allergic cross-sensitivity between penicillin, carbapenem, and monobactam antibiotics: what are the chances? Ann Pharmacother. 2009;43:304\u201315.","journal-title":"Ann Pharmacother"},{"issue":"4","key":"9567_CR23","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/j.diagmicrobio.2007.10.018","volume":"59","author":"RN Jones","year":"2007","unstructured":"Jones RN, Sader HS, Fritsche TR, Janechek MJ. Selection of a surrogate \u03b2-lactam testing agent for initial susceptibility testing of doripenem, a new carbapenem. Diagn Microbiol Infect Dis. 2007;59(4):467\u201372.","journal-title":"Diagn Microbiol Infect Dis"}],"container-title":["International Journal of Clinical Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11096-011-9567-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11096-011-9567-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11096-011-9567-1","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,17]],"date-time":"2019-06-17T00:48:00Z","timestamp":1560732480000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11096-011-9567-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,10,8]]},"references-count":23,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2011,12]]}},"alternative-id":["9567"],"URL":"https:\/\/doi.org\/10.1007\/s11096-011-9567-1","relation":{},"ISSN":["2210-7703","2210-7711"],"issn-type":[{"value":"2210-7703","type":"print"},{"value":"2210-7711","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,10,8]]}}}